# Oxaliplatin Biliary Tract Cancer trial NCT07916844

> NCT07916844 tests hepatic arterial infusion chemotherapy versus capecitabine in resected biliary tract cancer; ChEMBL and 1231 oxaliplatin studies.

Data as of 2026-11-11 · Published 2026-11-11 · Updated 2026-11-11 · https://bioq.bio/blog/en/oxaliplatin-nct07916844-biliary-tract-cancer

![BioQ result page for the query oxaliplatin, showing ChEMBL potency rows and a list of registered ClinicalTrials.gov studies.](https://bioq.bio/blog/img/oxaliplatin-nct07916844-biliary-tract-cancer/en/hero.webp)

Trial NCT07916844 is a PHASE3 study that compares hepatic arterial infusion chemotherapy with capecitabine as adjuvant therapy after resection of biliary tract cancer. For oxaliplatin, BioQ finds 3 ChEMBL targets, of which 2 have exact measurements (best pChEMBL 6.57), and 1231 registered studies, 233 of them PHASE3. Data are as of 2026-11-11.

## What we asked about the oxaliplatin trial in biliary tract cancer

The registry entry is titled "Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer". The sponsor is Zhai Wenlong, the phase is PHASE3, and the planned start is 2026-11-30. The listed conditions are Biliary Tract Cancer, Cholangiocarcinoma and Gallbladder Cancer.

The trial is filed under oxaliplatin as an intervention. The registry text we worked from does not spell out the infusion regimen, so we do not state which drugs make up the arm. We asked a narrower question: what does public data already say about oxaliplatin itself?

- How strong are the measured activities of oxaliplatin in ChEMBL?
- How many other trials list oxaliplatin, and at which phases?
- How is the compound identified across databases?

## What BioQ returned

One query, "oxaliplatin", ran 3 engine queries against 3 distinct resources (ChEMBL, ClinicalTrials.gov and PubChem). Together they took 0.75 engine seconds.

### Measured potency in ChEMBL

The current ChEMBL release maps oxaliplatin to CHEMBL414804 and lists 3 targets. pChEMBL is the negative log10 of the molar potency, so a higher value means a lower concentration was needed.

| ChEMBL target | Gene | Best pChEMBL | Type | Exact measurements |
|---|---|---|---|---|
| CHEMBL614455 | — | 6.57 | IC50 | 1 |
| CHEMBL614004 | — | 6.32 | IC50 | 3 |
| CHEMBL612545 | — | — | — | 0 |

![BioQ targets view for oxaliplatin listing ChEMBL targets with best pChEMBL values and counts of exact measurements](https://bioq.bio/blog/img/oxaliplatin-nct07916844-biliary-tract-cancer/en/targets.webp)
*Targets view for the query oxaliplatin: best pChEMBL and exact measurements per ChEMBL target.*

Two targets carry exact measurements: CHEMBL614455 (best pChEMBL 6.57, IC50, 1 exact measurement) and CHEMBL614004 (6.32, IC50, 3 exact measurements). The third, CHEMBL612545, has 0 exact measurements and no pChEMBL value. The gene column is empty for all three rows, so ChEMBL does not map them to a gene here.

### Other trials of oxaliplatin

ClinicalTrials.gov matches 1231 studies with oxaliplatin as an intervention. By phase: 293 PHASE1, 800 PHASE2 and 233 PHASE3. The table below is a page of 6 studies, not a ranking and not a biliary tract selection.

| Trial | Phase | Status | Sponsor | Start | Enrollment |
|---|---|---|---|---|---|
| NCT01308840 | PHASE2 | COMPLETED | University of Rochester | 2010-12 | 31 |
| NCT00403624 | PHASE1/PHASE2 | COMPLETED | Sanofi | 2001-07 | 38 |
| NCT00873275 | PHASE1 | COMPLETED | City of Hope Medical Center | 2009-03 | 11 |
| NCT05307198 | PHASE2 | UNKNOWN | Second Affiliated Hospital, Zhejiang Uni | 2022-05 | 38 |
| NCT02730546 | PHASE1/PHASE2 | COMPLETED | Mayo Clinic | 2016-06 | 31 |
| NCT03349866 | PHASE2 | UNKNOWN | Hebei Medical University | 2017-11 | 48 |

### Compound identity

PubChem lists oxaliplatin as CID 9887054 with the InChIKey ZROHGHOFXNOHSO-BNTLRKBRSA-L and 58 synonyms. The PubChem record carries no ChEMBL identifier of its own. The link to CHEMBL414804 came from the ChEMBL lookup by name.

## What it means and how to read it

The potency rows are IC50 values attached to ChEMBL target records. Because the gene column is empty, they are not protein-target affinities in the way a kinase inhibitor's would be. The record behind each value should be opened and checked, including the assay type and the system tested, before drawing a mechanistic conclusion.

The trial landscape shows that oxaliplatin is a heavily studied agent. The 233 PHASE3 studies sit next to 800 PHASE2 studies, and NCT07916844 is one more entry in a large registry. What distinguishes it is the setting: a comparison of hepatic arterial infusion against capecitabine after resection, with start planned for 2026-11-30. That setting does not follow from the ChEMBL numbers.

For a trial watch, the practical use of these results is orientation. They show what is already measured for the compound, how crowded the oxaliplatin trial space is, and which identifiers connect the databases. Done by hand, this would mean opening ChEMBL, ClinicalTrials.gov and PubChem separately and matching the compound by name or identifier each time. BioQ did it in one query, and each block names its source.

## How to reproduce it in BioQ

1. Open BioQ and enter the compound name as the query, exactly as below.

```text
oxaliplatin
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3Doxaliplatin)

2. Read the targets view first: check the ChEMBL identifier, the best pChEMBL and the count of exact measurements per target.
3. Open the clinical trials block and note the phase counts for all matched studies, then narrow by condition if you want biliary tract studies only.
4. Check the compound identity block for the PubChem CID and the number of synonyms before searching other databases by name.
5. Look up NCT07916844 directly to read the full registry record, since the intervention list there decides which agents the arms contain.

## Limits: what the data do not show

- The facts do not give the dose, schedule or exact drug combination of the infusion arm in NCT07916844, so nothing here describes what patients would receive.
- The trial has a planned start of 2026-11-30, after the data date of 2026-11-11, and there are no results. Nothing here speaks to outcome, benefit or harm.
- The ChEMBL numbers rest on 1 and 3 exact measurements for the two targets with values. They are thin and may come from assays unrelated to biliary tract cancer.
- Dependency of any target in cancer cell models was not part of this query, and a mechanism-of-action annotation was not returned, so we make no claim on either.
- The 6 studies in the table are one page of 1231, and the phase counts are for all matched studies, not for biliary tract cancer.
- Registry data and ChEMBL releases change. Rerun the query before citing any number.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-11 (3 queries, 0.8 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/chembl_potency`, `/clinicaltrials`, `/compound`

## Sources
- Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer (2026) — [https://clinicaltrials.gov/study/NCT07916844](https://clinicaltrials.gov/study/NCT07916844)

Run the same query yourself: [oxaliplatin](https://bioq.bio/login?next=%2Fapp%23q%3Doxaliplatin)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`oxaliplatin`](https://bioq.bio/login?next=%2Fapp%23q%3Doxaliplatin)

## Frequently asked questions

### What does trial NCT07916844 test?

It is a PHASE3 study from sponsor Zhai Wenlong comparing hepatic arterial infusion chemotherapy with capecitabine as adjuvant therapy for resected biliary tract cancer. Planned start is 2026-11-30.

### How many oxaliplatin trials are registered on ClinicalTrials.gov?

BioQ matched 1231 studies with oxaliplatin as an intervention: 293 PHASE1, 800 PHASE2 and 233 PHASE3, as of 2026-11-11.

### What is the measured potency of oxaliplatin in ChEMBL?

ChEMBL lists 3 targets for CHEMBL414804, 2 of them with exact measurements. The best pChEMBL values are 6.57 (1 exact measurement) and 6.32 (3 exact measurements), both IC50.

### What is the PubChem identity of oxaliplatin?

PubChem CID 9887054, InChIKey ZROHGHOFXNOHSO-BNTLRKBRSA-L, with 58 synonyms.

### How long did the BioQ query take?

The 3 engine queries across 3 distinct resources took 0.75 engine seconds in total.

## Sources

- Trial: [Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer](https://clinicaltrials.gov/study/NCT07916844) (2026)
- Dataset: [ClinicalTrials.gov](https://clinicaltrials.gov/)
- Dataset: [PubChem](https://pubchem.ncbi.nlm.nih.gov/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
